From: Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Pat. # | DLCO (% pred.) | pO2(mmHg) | 6 MWD (m) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
baseline | 3 months | p | 6 months | p | baseline | 3 months | p | 6 months | p | baseline | 6 months | p | |
1 | 46 | 51 | 68 | 67 | 68 | 700 | 730 | ||||||
2 | 38 | 37 | 38 | 61 | 67 | 69 | 500 | 530 | |||||
3 | 37 | 40 | 62 | 67 | 69 | ||||||||
4 | 26 | 33 | 39 | 55 | 56 | 62 | 420 | 510 | |||||
5 | 15 | 12 | 18 | 52 | 41 | 48 | |||||||
6 | 23 | 25 | 24 | 69 | 67 | 70 | 510 | 535 | |||||
7 | 12 | 15 | 19 | 55 | 50 | 56 | 300 | 370 | |||||
8 | 22 | 30 | 59 | 63 | |||||||||
9 | 34 | 36 | 36 | 60 | 62 | 56 | 525 | ||||||
10 | 27 | 32 | 32 | 57 | 64 | 68 | 540 | ||||||
Mean ± SEM | 28.0 ± 3.4 | 27.1 ± 3.8 | 0.15 | 32.7 ± 3.3 | 0.004 | 59.8 ± 1.7 | 60.1 ± 3.1 | 0.91 | 62.9 ± 2.3 | 0.88 | 486 ± 65 | 535 ± 57 | 0.02 |